Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab extension study in chronic plaque psoriasis
NCT03010527Phase 2Completed
- Sponsor
- UCB
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, double-blind trial of bimekizumab in plaque psoriasis (4 arms), sponsored by UCB. Primary endpoint: Incidence of Treatment Emergent Adverse Events at Week 64. Started Dec 2016; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03010527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010527.